NetraMark Raises $3.5 Million to Advance AI-Driven Clinical Trial Analytics

NetraMark Holdings ( (TSE:AIAI) ) has issued an announcement.

NetraMark Holdings Inc., a Toronto-based AI specialist focused on the pharmaceutical sector, has developed NetraAI, a generative AI and machine-learning platform designed to parse small clinical trial datasets into explainable subsets. By using a novel topology-based algorithm, the system aims to reduce overfitting and generate actionable hypotheses on treatment response, placebo effects, and adverse events, helping drug developers segment diseases and patients more accurately.

The company has closed the second and final tranche of its non-brokered private placement, issuing 390,000 units at $1.00 each for gross proceeds of $390,000, bringing the total financing to $3.5 million and lifting the share count to 92,223,699. Each unit comprises one common share and half a warrant exercisable at $1.35 for two years, with the funds earmarked for working capital and general corporate purposes, while insider participation triggered related-party rules but qualified for exemptions, underscoring continued internal support as NetraMark advances its AI-driven clinical trial analytics business.

More about NetraMark Holdings

NetraMark Holdings Inc. is an artificial intelligence company focused on developing generative AI and machine-learning solutions for the pharmaceutical industry, with a particular emphasis on transforming clinical trials through precision analytics. Its NetraAI platform uses a topology-based algorithm and focus mechanisms to segment small patient datasets into meaningful subsets, aiming to reduce overfitting, improve trial insights, and enhance the chances of clinical success by accurately classifying patients and disease subtypes.

Unlike many AI methods that assign every patient to a class and risk drowning out critical signals, NetraAI separates explainable and unexplainable data to derive hypotheses about treatment response, placebo effects, and adverse events. This approach allows NetraMark to work effectively with smaller datasets than traditional AI or ML systems, positioning the company as a specialized provider of advanced analytics for drug developers seeking better trial design and decision-making.

Average Trading Volume: 53,167

Technical Sentiment Signal: Hold

Current Market Cap: C$93.64M

Learn more about AIAI stock on TipRanks’ Stock Analysis page.